2025 年血液學和腫瘤學檢測全球市場報告

預計未來幾年血液學和腫瘤學檢測的市場規模將快速成長。到 2029 年，這一數字將成長至 68.3 億美元，複合年成長率為 14.6%。預測期內的成長可歸因於個人化醫療趨勢、人工智慧整合、老年人口成長、基因組研究的進步以及對癌症早期檢測的需求不斷增加。預測期內的關鍵趨勢包括基因組檢測的技術進步、非侵入性檢測的液態切片、行業合作和夥伴關係、監管格局和標準化以及技術進步。

預計血癌發生率的上升將推動血液學和腫瘤學檢測市場的成長。血液系統癌症包括一組影響血液、骨髓和淋巴系統的血源性癌症，包括白血病、淋巴瘤和骨髓瘤等疾病。這些疾病的早期診斷非常重要，而血液和腫瘤檢測在這方面起著至關重要的作用。例如，美國癌症協會預測，到 2023 年，白血病將影響約 59,610 名美國，並造成 23,710 人死亡。此外，非何傑金氏淋巴瘤預計將影響美國80,550 人，並導致 20,180 人死亡。因此，血癌發生率的不斷上升是推動血液學和腫瘤學檢測市場向前發展的關鍵因素。

預計未來幾年醫療保健支出的增加將推動血液學和腫瘤學檢測市場的成長。醫療支出是指特定地區、國家或經濟體在一定時期內分配給醫療保健部門的公共和私人資金總額。將這些資金適當分配給血液腫瘤學檢測將提高診斷的準確性，實現個人化的治療方法，並改善複雜造血腫瘤領域的患者預後。例如，英國政府機構國家統計局 2024 年 5 月的報告顯示，2022 年至 2023 年，醫療保健總支出名義上增加了 5.6%。而 2022 年的成長率僅 0.9%。因此，醫療保健支出的增加正在推動血液腫瘤學檢測市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第 4 章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情以及復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球血液學和腫瘤學檢測市場的 PESTEL 分析（政治、社會、技術、環境、法律、促進因素、限制因素）
• 最終用途產業分析
• 全球血液學和腫瘤學檢測市場：成長率分析
• 全球血液學和腫瘤學檢測市場表現：規模和成長，2019 年至 2024 年
• 全球血液學和腫瘤學檢測市場預測：規模和成長，2024-2029 年，2034 年
• 全球血液學和腫瘤學檢測總目標市場 (TAM)

第6章 市場細分

• 全球血液學和腫瘤學檢測市場（按產品和服務、績效和預測）2019-2024、2024-2029、2034
• 檢測套件和試劑
• 服務
• 全球血液學和腫瘤學檢測市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
• 白血病
• 淋巴瘤
• 多發性骨髓瘤
• 其他
• 全球血液學和腫瘤學檢測市場（按技術、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 聚合酵素鏈鎖反應（PCR）
• 免疫組織化學 (IHC)
• 次世代定序（NGS）
• 其他
• 全球血液學和腫瘤學檢測市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
• 醫院
• 學術研究所
• 其他
• 全球血液學和腫瘤學檢測市場：檢測試劑套件和試劑按類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
• PCR套件
• 次世代定序(NGS)套件
• 流式細胞技術試劑
• ELISA套件
• 抗體
• 全球血液學和腫瘤學檢測市場：按類型、表現和預測分類的服務細分，2019-2024 年、2024-2029 年、2034 年
• 檢驗服務
• 諮詢服務
• 資料分析服務

第7章 區域和國家分析

• 全球血液學及腫瘤學檢測市場各地區、績效及預測，2019-2024、2024-2029、2034
• 全球血液學和腫瘤學檢測市場（按國家/地區分類）、績效和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第 17 章 德國市場

第 18 章 法國市場

第 19 章：義大利市場

第 20 章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第 25 章：加拿大市場

第26章 南美洲市場

第 27 章：巴西市場

第28章 中東市場

第 29 章：非洲市場

第 30 章競爭格局與公司概況

• 血液學和腫瘤學檢測市場：競爭格局
• 血液學和腫瘤學檢測市場：公司簡介
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• Qiagen NV
• Bio-Rad Laboratories Inc.
• Archerdx Inc.
• ARUP Laboratories Inc.
• Asuragen Inc.
• Adaptive Biotechnologies Corp.
• Cepheid Inc.
• EntroGen Inc.
• CORE Diagnostics Inc.
• Genoptix Inc.
• GenPath Diagnostics
• NeoGenomics Laboratories Inc.
• Siemens AG
• Sysmex Corporation
• Laboratory Corporation of America Holdings

第 32 章 全球市場競爭基準化分析與儀表板

第33章 重大併購

第 34 章 近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029 年血液學和腫瘤學檢測市場：提供新機會的國家
• 2029 年血液學和腫瘤學檢測市場：細分市場將帶來新機會
• 2029 年血液學和腫瘤學檢測市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第 36 章 附錄

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from$3.5 billion in 2024 to $3.96 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing cancer incidence, growing awareness and screening programs, rising healthcare expenditure, increasing adoption of personalized medicine, and increasing incidence of blood disorders

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to personalized medicine trends, integration of artificial intelligence, rising geriatric population, advancements in genomic research, and rising demand for early cancer detection. Major trends in the forecast period include technological advancements in genomic testing, liquid biopsy for non-invasive testing, collaborations and partnerships in the industry, regulatory landscape and standardization, and technological advancements.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The increasing healthcare expenditure is projected to drive the growth of the hemato-oncology testing market in the coming years. Healthcare expenditure refers to the total funds, both public and private, allocated to the healthcare sector within a specific geographical area, country, or economy over a defined period. Proper allocation of these funds towards hemato-oncology testing enhances diagnostic accuracy, enables personalized treatment approaches, and improves patient outcomes in the complex field of hematopoietic tumors. For example, a report from the Office for National Statistics, a UK-based government department, revealed in May 2024 that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth of only 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the hemato-oncology testing market.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
• 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma; Other Cancers
• 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
• 4) By End User: Hospitals; Academic And Research Institutes; Other End Users
• Subsegments:
• 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; ELISA Kits; Antibodies
• 2) By Services: Testing Services; Consultation Services; Data Analysis Services
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemato Oncology Testing Market Characteristics

3. Hemato Oncology Testing Market Trends And Strategies

4. Hemato Oncology Testing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hemato Oncology Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hemato Oncology Testing Market Growth Rate Analysis
• 5.4. Global Hemato Oncology Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hemato Oncology Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hemato Oncology Testing Total Addressable Market (TAM)

6. Hemato Oncology Testing Market Segmentation

• 6.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Assay Kits And Reagents
• Services
• 6.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Multiple Myeloma
• Other Cancers
• 6.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Other Technologies
• 6.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Academic And Research Institutes
• Other End Users
• 6.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCR Kits
• Next-Generation Sequencing (NGS) Kits
• Flow Cytometry Reagents
• ELISA Kits
• Antibodies
• 6.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing Services
• Consultation Services
• Data Analysis Services

7. Hemato Oncology Testing Market Regional And Country Analysis

• 7.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemato Oncology Testing Market

• 8.1. Asia-Pacific Hemato Oncology Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemato Oncology Testing Market

• 9.1. China Hemato Oncology Testing Market Overview
• 9.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemato Oncology Testing Market

• 10.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemato Oncology Testing Market

• 11.1. Japan Hemato Oncology Testing Market Overview
• 11.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemato Oncology Testing Market

• 12.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemato Oncology Testing Market

• 13.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemato Oncology Testing Market

• 14.1. South Korea Hemato Oncology Testing Market Overview
• 14.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemato Oncology Testing Market

• 15.1. Western Europe Hemato Oncology Testing Market Overview
• 15.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemato Oncology Testing Market

• 16.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemato Oncology Testing Market

• 17.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemato Oncology Testing Market

• 18.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemato Oncology Testing Market

• 19.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemato Oncology Testing Market

• 20.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemato Oncology Testing Market

• 21.1. Eastern Europe Hemato Oncology Testing Market Overview
• 21.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemato Oncology Testing Market

• 22.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemato Oncology Testing Market

• 23.1. North America Hemato Oncology Testing Market Overview
• 23.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemato Oncology Testing Market

• 24.1. USA Hemato Oncology Testing Market Overview
• 24.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemato Oncology Testing Market

• 25.1. Canada Hemato Oncology Testing Market Overview
• 25.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemato Oncology Testing Market

• 26.1. South America Hemato Oncology Testing Market Overview
• 26.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemato Oncology Testing Market

• 27.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemato Oncology Testing Market

• 28.1. Middle East Hemato Oncology Testing Market Overview
• 28.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemato Oncology Testing Market

• 29.1. Africa Hemato Oncology Testing Market Overview
• 29.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

• 30.1. Hemato Oncology Testing Market Competitive Landscape
• 30.2. Hemato Oncology Testing Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hemato Oncology Testing Market Other Major And Innovative Companies

• 31.1. Qiagen N.V.
• 31.2. Bio-Rad Laboratories Inc.
• 31.3. Archerdx Inc.
• 31.4. ARUP Laboratories Inc.
• 31.5. Asuragen Inc.
• 31.6. Adaptive Biotechnologies Corp.
• 31.7. Cepheid Inc.
• 31.8. EntroGen Inc.
• 31.9. CORE Diagnostics Inc.
• 31.10. Genoptix Inc.
• 31.11. GenPath Diagnostics
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Siemens AG
• 31.14. Sysmex Corporation
• 31.15. Laboratory Corporation of America Holdings

32. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

34. Recent Developments In The Hemato Oncology Testing Market

35. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

• 35.1 Hemato Oncology Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hemato Oncology Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hemato Oncology Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer